Literature DB >> 6460824

Pharmacokinetics of moxalactam in patients with normal and impaired renal function.

G R Aronoff, R S Sloan, F C Luft.   

Abstract

Moxalactam is the first representative of a new class of potent beta-lactam antibiotics. To establish dosage recommendations, the kinetics of moxalactam elimination were studied in 20 patients with various degrees of renal dysfunction. After a 1-g intravenous bolus injection, the elimination half-life increased from 2.2 +/- 0.1 hr in normal subjects to 22.3 +/- 1.7 hr in anuric patients. Similar correlations were shown between the rate of creatinine clearance and the rate of plasma clearance, the rate of renal clearance, and the overall elimination rate constant of moxalactam. No changes in the distribution volumes or metabolic clearance rates of moxalactam were detected. A nomogram for adjustment of moxalactam dosage in patients with any level of renal function was generated, and specific recommendations for moxalactam dosage are discussed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6460824     DOI: 10.1093/infdis/145.3.365

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  7 in total

1.  Moxalactam kinetics during continuous ambulatory peritoneal dialysis after intraperitoneal administration.

Authors:  T E Jones; R W Milne; Y Mudaliar; L N Sansom
Journal:  Antimicrob Agents Chemother       Date:  1985-08       Impact factor: 5.191

Review 2.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

3.  Population Pharmacokinetics and Dosing Regimen Optimization of Latamoxef in Chinese Children.

Authors:  Yang Wang; Dan Sun; Yan Mei; Sanlan Wu; Xinlin Li; Sichan Li; Jun Wang; Liuliu Gao; Hua Xu; Yali Tuo
Journal:  Pharmaceutics       Date:  2022-05-11       Impact factor: 6.525

4.  Pharmacokinetics of moxalactam in elderly subjects.

Authors:  M H Andritz; R P Smith; A L Baltch; P E Griffin; J V Conroy; N Sutphen; M C Hammer
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

5.  High performance liquid chromatographic determination of moxalactam in human plasma and cerebrospinal fluid.

Authors:  J Nielsen; G Karlaganis; H M von Hattingberg; U B Schaad
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

6.  Steady-state moxalactam pharmacokinetics in patients: noncompartmental versus two-compartmental analysis.

Authors:  D J Swanson; D P Reitberg; I L Smith; P B Wels; J J Schentag
Journal:  J Pharmacokinet Biopharm       Date:  1983-08

Review 7.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.